Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review.
Future Oncol
; 17(20): 2671-2681, 2021 Jul.
Article
em En
| MEDLINE
| ID: mdl-33880963
Lay abstract Recent years have seen growing attention toward quality of life (QoL) in medical oncology clinical trials and statistical measurement of this aspect of cancer treatment. Nonetheless, although most clinicians and researchers agree that QoL should represent a fundamental component of clinical trials, the inclusion of QoL results is still inadequate, and our systematic review confirms that implementing the inclusion of QoL remains an urgent need.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
1_ASSA2030
/
2_ODS3
/
6_ODS3_enfermedades_notrasmisibles
Problema de saúde:
1_doencas_nao_transmissiveis
/
2_muertes_prematuras_enfermedades_notrasmisibles
/
6_kidney_renal_pelvis_ureter_cancer
Assunto principal:
Qualidade de Vida
/
Carcinoma de Células Renais
/
Neoplasias Renais
/
Recidiva Local de Neoplasia
/
Antineoplásicos
Tipo de estudo:
Systematic_reviews
Aspecto:
Patient_preference
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Itália